The use of baclofen in neonates has been minimally reported. We report on two term neonates who were treated successfully for hypertonia with baclofen.
INTRODUCTION
Neonatal hypertonia, resulting from severe hypoxic-ischemic brain injury or developmental brain disorders, may lead to severe functional disability. Severe hypertonia can be associated with feeding difficulties, pain, discomfort and severe disabling joint contractures. Providing adequate care for these hypertonic neonates is often a challenging situation both for the caretakers and family. Medications are rarely employed to treat neonatal hypertonia.
Baclofen is a GABA agonist that is used to reduce muscle tone in children with cerebral palsy and in adults with various spastic disorders. It is absorbed rapidly enterally and readily crosses the blood-brain barrier. Baclofen causes presynaptic inhibition, resulting in inhibition of mono-and polysynpatic reflexes. 1 Symptomatic relief of severe chronic spasticity has been noted with baclofen therapy. 2 The use of baclofen in neonates for severe muscle spasticity has not been well documented. We report two cases detailing the use of baclofen in term neonates with severe muscle hypertonia. Parental consent was obtained prior to the initiation of baclofen in each patient. Both neonates were evaluated by the same occupational therapist using the modified Ashworth scale (MAS). Although the efficacy of the MAS tool has been shown in adults, it is utilized routinely to assess hypertonicity in all age groups. [3] [4] [5] Tone is assessed on a scale from 0 to 4. The scale begins at 0, representing no increase in tone and ranges to 4, which is a considerable increase in tone with difficulty in passive movements.
CASE REPORTS Patient #1
A 4030-g male was born at term to a 24-year-old gravida 1 para 1 woman with an unremarkable pregnancy. Her blood type was A positive, antibody negative, rubella immune, Hepatitis B surface antigen negative, RPR nonreactive, Group B Streptococcus positive and PPD positive with negative chest radiograph results. She presented at an outside hospital in labor, with rupture of membranes 4 hours prior to delivery and received three doses of ampicillin for GBS prophylaxis. The newborn male was born by vaginal delivery with APGARs of 2 and 3, at 1 and 5 minutes, respectively, with no documented 10-and 15-minute APGAR scores. He did require CPR and intubation in the delivery room for profound bradycardia and apnea.
Initial NICU course was complicated by profound four-extremity hypertonia, seizures and respiratory failure during his first month of life, but was subsequently extubated to room air. He was noted to have an absent gag and suck reflex, abnormal facial movements and required frequent suctioning. He received phenobarbital for seizure prophylaxis and had an abnormal initial EEG. Occupational therapy was consulted for tone management and a general developmental evaluation. Phenobarbital was successfully discontinued and follow-up EEG on day of life, DOL 32 showed no electrographic seizures. Repeat brain MRI was diffusely abnormal and consistent with late subacute severe hypoxic-ischemic injury in both basal ganglia and perirolandic regions with evidence of significant white matter injury.
Neurodevelopmental handling and positioning techniques were introduced into the infant's care to manage progressing hypertonia. Reassessment on DOL 32 noted severe flexor synergy with scissoring of lower extremities, cortical fisting, arching and right head preference. The infant's MAS was 3 bordering on 4 in both upper and lower extremities. Baclofen 0.5 mg/kg/day PG divided q6 h was initiated on DOL 36. Follow-up assessment at DOL 39 noted a significant decrease in arching and uncomfortable behaviors. The MAS on DOL 39 was 3 throughout the upper extremities, and decreased to 1 throughout the lower extremity, trunk and neck. Care and positioning of the infant was markedly improved after the introduction of baclofen. The infant was able to maintain flexion at his trunk and could tolerate gentle range of motion through all extremities. This improvement allowed better engagement with his environment, parents and caretakers.
Baclofen was increased by 0.5 mg/kg/day each week for a final dose of 1.5 mg/kg/day. MAS decreased to 2 in the lower extremities and 3 in the upper extremities. Final assessment prior to transfer to a rehabilitation hospital noted increased tolerance for both upper and lower range of motion bilaterally. At follow-up at age 4 months, this neonate was fixing and following more consistently, but was still receiving mostly gavage tube feeds. The patient was still on baclofen and his MAS scores were 1 in the lower extremities and 2 in the upper extremities (Figure 1) . He was seizure free at this time.
Patient #2
A 2780-g nondysmorphic female was born at term to a 28-year-old gravida 3 para 3 woman who had a pregnancy notable for a 17-week ultrasound visualizing a clubfoot. Amniocentesis was declined and a level II ultrasound noted no additional abnormalities. Her blood type was A positive, antibody negative, rubella immune, Hepatitis B surface antigen negative, RPR nonreactive and Group B streptococcus negative. She presented at a community hospital in labor, with rupture of membranes approximately 3 hours prior to delivery. The newborn was born by normal spontaneous vaginal delivery with APGARs of 8 and then 3, at 1 and 5 minutes, respectively. She went on to develop significant secretions and mild tachypnea and grunting in the delivery room requiring vigorous suctioning, facial CPAP and supplemental oxygen. Chest radiograph showed low long volumes. Hypertonia of the upper extremities with hand clenching was also noted and the newborn was transported to our NICU.
Her hospital course was complicated by severe four-extremity hypertonia, seizures and transient respiratory distress. She was stable on room air within 24 hours of life. Neurology was consulted to evaluate the hypertonia and seizures. Brain MRI on DOL 2 demonstrated a mildly abnormal cortex without focality. EMG on DOL 3 was within normal limits. EEG on DOL 3 was abnormal due to presence of relatively excessive for age sharp activity over the left hemisphere, centrotemporal and occipital regions. Phenobarbital was initiated and a repeat EEG on DOL 13 was essentially normal exhibiting no excessive sharp transients or electrographic seizures. A genetics workup did not reveal any specific disorder as well.
Occupational therapy was consulted for hypertonia and a general developmental evaluation. DOL 1 assessment noted significant hypertonia, left side greater than right, lower extremities greater than upper extremities. The MAS was assessed then as 2 throughout all extremities. Subsequent evaluations noted a marked increase in her hypertonia and concern for observed infant discomfort during routine care (i.e. diaper change, position change and nurturing interaction with parents). Neurodevelopmental handling and positioning techniques were introduced into her care to manage worsening hypertonia. She exhibited no immediate or sustained signs of relief from her hypertonia with these inhibitory techniques. Her progressive hypertonia made positioning and hand splinting very difficult. The level of tonicity in the left lower extremity was not evaluated secondary to a casted clubfoot. Baclofen 0.35 mg/kg/day PG divided q6 h was initiated on DOL 24. At this time, the right upper and lower extremities had an MAS 4 and the left upper extremity had an MAS 3. The dose was increased by 0.5 mg/kg/week to a final dose of 1 mg/kg/day.
After introduction of baclofen, this neonate was able to tolerate additional therapeutic activities such as developmental prone positioning, right-hand splinting and, more importantly, nurturing/social activities with her family. MAS decreased to 2 in all extremities over the next 2 weeks and the infant was then transferred to a rehabilitation hospital on DOL 47. Follow-up at age 4 months revealed a MAS of 1 throughout all her extremities and trunk (Figure 2) , with her being maintained exclusively on gavage tube feeds. She was seizure free at this time. 
DISCUSSION
The use of baclofen in the neonatal period has not been well documented. Based on the limited experience using baclofen for the prevention and treatment of neonatal seizures following intrauterine baclofen exposure, a starting dose of 0.5 mg/kg/day PG was selected. 6 The enteral route was selected due to ease of administration. The intrathecal route has been associated with cardiovascular collapse, CNS depression and respiratory failure, and is rarely used in infants. 2 The dose was titrated to clinical response or a decrease in MAS.
Following the initiation of baclofen therapy, both infants exhibited improved regulation of tone and a decrease in MAS. Occupational therapy routinely evaluated each neonate and reported to the care team any changes in tone and range of motion. These changes were taken into consideration in determining baclofen dosage. Patient #1's MAS decreased from 4 to 2 and 4 to 1 in the upper and lower extremities, respectively, with a final baclofen dose of 1.5 mg/kg/day. Patient #2's MAS decreased from 4 to 1 and 3 to 1 in the right lower and left upper extremities, respectively, with a final baclofen dose of 1 mg/kg/day. No adverse drug effects were reported in either patient. Both infants displayed improved range of motion, a perceived decrease in pain and improved tolerance for routine care. Tolerance for socialization and nurturing time with family was also enhanced. The implementation of baclofen allowed for extremity splinting preventing further loss of range of motion. Neither patient exhibited known side effects, which may include drowsiness, feeding intolerance, vomiting and constipation. 2 There have been some reports about baclofen's effect on increasing seizure activity; 7, 8 however, neither of our patients had any increase in seizure frequency on baclofen therapy.
We report the successful and apparently safe use of baclofen for two neonates with marked hypertonia. The use of baclofen in the newborn period has not been previously well documented. We hope these reports will help stimulate further studies into determining optimal dosing and long-term outcomes.
